IL249098A0 - Methods and preparations for the treatment of allergy and inflammatory diseases - Google Patents

Methods and preparations for the treatment of allergy and inflammatory diseases

Info

Publication number
IL249098A0
IL249098A0 IL249098A IL24909816A IL249098A0 IL 249098 A0 IL249098 A0 IL 249098A0 IL 249098 A IL249098 A IL 249098A IL 24909816 A IL24909816 A IL 24909816A IL 249098 A0 IL249098 A0 IL 249098A0
Authority
IL
Israel
Prior art keywords
compositions
methods
inflammatory diseases
treating allergy
allergy
Prior art date
Application number
IL249098A
Other languages
English (en)
Hebrew (he)
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of IL249098A0 publication Critical patent/IL249098A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL249098A 2014-06-02 2016-11-21 Methods and preparations for the treatment of allergy and inflammatory diseases IL249098A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462006575P 2014-06-02 2014-06-02
PCT/US2015/033696 WO2015187637A1 (en) 2014-06-02 2015-06-02 Methods and compositions for treating allergy and inflammatory diseases

Publications (1)

Publication Number Publication Date
IL249098A0 true IL249098A0 (en) 2017-01-31

Family

ID=54767263

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249098A IL249098A0 (en) 2014-06-02 2016-11-21 Methods and preparations for the treatment of allergy and inflammatory diseases

Country Status (8)

Country Link
US (1) US20170095573A1 (https=)
EP (1) EP3148575B1 (https=)
JP (1) JP2017525655A (https=)
CN (1) CN106456736A (https=)
AU (1) AU2015270845B2 (https=)
CA (1) CA2950293A1 (https=)
IL (1) IL249098A0 (https=)
WO (1) WO2015187637A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127706A1 (en) * 2016-01-22 2017-07-27 Yale University Compositions and methods for inhibiting dkk-1
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US11007256B2 (en) * 2016-09-26 2021-05-18 The University Of Toledo Synthetic lipopeptide vaccines and immunotherapeutics
AU2017376460A1 (en) * 2016-12-13 2019-06-20 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
EP3618868A4 (en) * 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
CN111032087A (zh) * 2017-06-28 2020-04-17 小利兰·斯坦福大学托管委员会 用于dectin-2刺激和癌症免疫治疗的方法和组合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP7829485B2 (ja) 2019-12-20 2026-03-13 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
EP4114417A4 (en) * 2020-03-06 2024-08-14 OD Therapeutics Limited THERAPEUTIC AGENTS AND THEIR CONJUGATES
AU2021292488A1 (en) * 2020-06-15 2023-02-02 Monopar Therapeutics, Inc. Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (uPAR) for treatment of severe COVID-19 disease
CN112480244A (zh) * 2020-11-24 2021-03-12 华科同济干细胞基因工程有限公司 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂
EP4395761A4 (en) * 2021-08-31 2025-10-01 Ena Respiratory Pty Ltd ALLERGY TREATMENT
US20250223364A1 (en) * 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
CN117426352B (zh) * 2023-12-08 2024-03-08 中国中医科学院中药研究所 一种间质性肺病变动物模型的构建方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
CN103800906B (zh) * 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
BR112012028522A2 (pt) * 2010-05-07 2016-07-19 Baylor Res Inst sensibilização cruzada mediada por imunorreceptores de células dendríticas (dcir) de células t humanas cd8+
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
CN103237549A (zh) * 2010-10-01 2013-08-07 帆德制药股份有限公司 过敏性疾病的治疗方法
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
GB2506820A (en) * 2011-07-11 2014-04-09 Sourcebooks Inc Customizable and interactive book system
WO2013033104A1 (en) * 2011-08-29 2013-03-07 Baylor Research Institute CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2)
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions

Also Published As

Publication number Publication date
AU2015270845A1 (en) 2016-12-08
EP3148575B1 (en) 2019-08-21
CA2950293A1 (en) 2015-12-10
AU2015270845B2 (en) 2019-09-12
CN106456736A (zh) 2017-02-22
WO2015187637A1 (en) 2015-12-10
US20170095573A1 (en) 2017-04-06
EP3148575A4 (en) 2018-01-24
EP3148575A1 (en) 2017-04-05
JP2017525655A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
IL249098A0 (en) Methods and preparations for the treatment of allergy and inflammatory diseases
GB2535253B (en) Compositions and methods
IL246791A0 (en) Compositions and methods for treating eye diseases
AP2017009674A0 (en) Methods and compositions for treating ulcers
IL257561A (en) Methods for treating inflammatory diseases
IL253118A0 (en) Methods for treating inflammatory diseases
IL251759A0 (en) Preparations and methods for treating insomnia
PT3189074T (pt) Composições e métodos para tratar e prevenir a inflamação
GB201417828D0 (en) New methods and compositions
EP3126004A4 (en) Methods and compositions for treating inflammatory disorders
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
SG11201704829QA (en) Methods and compositions for treating brain diseases
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
HUE056154T2 (hu) Pektin készítmények gyulladásos betegségek megelõzésére és kezelésére
GB2537783B (en) Compositions used in treating inflammatory and autoimmune diseases
IL252707B (en) Compositions and methods for treating diseases
EP3523433C0 (en) MEANS AND METHODS FOR TREATING INFLAMMATORY DISEASES
EP3107998A4 (en) Compositions and methods for treating autoimmune and inflammatory diseases
GB201402915D0 (en) Compositions and methods
IL250244A0 (en) Prevention and treatment of inflammatory skin diseases
GB201521083D0 (en) Compositions for treatment and methods thereof